Five patients with metastatic pancreatic endocrine tumours injected a long acting somatostatin analogue (SMS 201-995) 50 micrograms subcutaneously every 12 hours and were followed up for three to six months. Treatment aimed at controlling excess secretion of hormone by the tumours thereby bringing symptomatic relief. Four patients showed a significant reduction in tumour related hormone concent...

The purpose of this study was to examine the effect of high-intensity physical activity during training on the biochemical status of thiamin and riboflavin in athletes. Thiamin and riboflavin concentrations in whole blood of a group of 19 athletes (6 men and 13 women) were measured during a low-intensity preparatory period and compared with measurements taken during a high-intensity training pe...

BACKGROUND The Cognitive Changes and Retirement among Senior Surgeons (CCRASS) study suggested that although subjective cognitive awareness may play a role in surgeons' retirement decisions, self-perceived cognitive decline did not predict objective cognitive performance. This article summarizes results from all participants who completed the survey portion of the CCRASS study. STUDY DESIGN A...

OBJECTIVE High-sensitivity C-reactive protein (hs-CRP) rises with cardiac injury/ischemia. We evaluated its efficacy in aiding in the identification of an acute coronary syndrome (ACS) in patients (pts) admitted to the chest pain unit (CPU) for possible ACS. METHODS Retrospective study of all patients admitted to the CPU with chest pain who underwent hs-CRP testing as part of their CPU evalua...

Manoj N. Obeyesekere, George J. Klein, Simon Modi, Peter Leong-Sit, Lorne J. Gula, Raymond Tachycardia Syndrome, Long-QT Syndrome, and Catecholaminergic Polymorphic Ventricular How to Perform and Interpret Provocative Testing for the Diagnosis of Brugada Print ISSN: 1941-3149. Online ISSN: 1941-3084 Copyright © 2011 American Heart Association, Inc. All rights reserved. Avenue, Dallas, TX 75231 ...

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 995 1. Melatonin Biosynthesis and Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 997 1.1 Regulation of Melatonin Biosynthesis . . . . . . . . . . . . . . . . . . . . ....